Diagnostic Center | March 12, 2024
Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Comprehensive clinical development programs being initiated for each investigational candidate
The company has received five final approvals
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
The product will be manufactured at Lupin's Pithampur facility in India
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Subscribe To Our Newsletter & Stay Updated
